Merck Profit Beats Forecasts, Keeps 2012 Sales Outlook

Merck reported higher-than-expected quarterly results on Friday and said it continued to expect full-year revenue to be at or near 2011 levels on a constant currency basis.


The company reported third-quarter earnings excluding items of 95 cents a share, just above last year's 94 cents per share.

Revenue fell to $11.5 billion from $12.02 billion a year ago.

Analysts expected Merck to post earnings excluding items of 92 cents a share on $11.6 billion in revenue, according to a Thomson Reuters estimate.

In pre-market trade, Merck shares were flat.

The company said worldwide sales of diabetes drugs Januvia and Janumet rose 15 percent in the quarter to $1.4 billion. On the other hand, sales of cholesterol drugs Zetia and Vytorin declined 1 percent to $1.1 billion.

The company also reported a 55 percent drop in sales of Singulair, an oral medicine for the treatment of Asthma, after the drug's U.S. patent expired in August. Sales of Singulair fell to $602 million in the quarter.

Click here to get the latest quote for Merck.

Contact Earnings


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More